On July 6, BeOne Medicines rose 3.17% in regular trading, trading at HK$188.9/share, with turnover of HK$231 million. The stock continues to be driven by positive clinical data from its flagship BTK inhibitor Brukinsa (zanubrutinib).

On the news front, Brukinsa's Phase 3 MANGROVE trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma achieved its primary endpoint of progression-free survival. The combination of Brukinsa plus rituximab demonstrated a 43% reduction in disease progression or death risk versus standard bendamustine-rituximab (HR=0.57). The company plans to present full results at an upcoming medical congress and pursue global regulatory submissions in the second half of the year.

Meanwhile, the broader biotechnology sector rallied strongly, with Innovent Biologics up 6.21%, Remegen up 6.44%, SKB Bio up 5.61%, 3SBio up 4.45%, and Akeso up 3.71%, providing additional upward momentum through sector linkage.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)